Literature DB >> 24079679

Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system.

John J Sim1, Simran K Bhandari, Jiaxiao Shi, In Lu A Liu, David A Calhoun, Elizabeth A McGlynn, Kamyar Kalantar-Zadeh, Steven J Jacobsen.   

Abstract

OBJECTIVE: To evaluate the prevalence of and characterize resistant hypertension in a large representative population with successful hypertension management and reliable health information. PATIENT AND METHODS: We performed a cross-sectional study using clinical encounter, laboratory, and administrative information from the Kaiser Permanente Southern California health system between January 1, 2006, and December 31, 2007. From individuals older than 17 years with hypertension, resistant hypertension was identified and prevalence was determined. Multivariable logistic regression was used to calculate odds ratios (ORs), with adjustments for demographic characteristics, clinical variables, and medication use.
RESULTS: Of 470,386 hypertensive individuals, 60,327 (12.8%) were identified as having resistant disease, representing 15.3% of those taking medications. Overall, 37,061 patients (7.9%) had uncontrolled hypertension while taking 3 or more medicines. The ORs (95% CIs) for resistant hypertension were greater for black race (1.68 [1.62-1.75]), older age (1.11 [1.10-1.11] for every 5-year increase), male sex (1.06 [1.03-1.10]), and obesity (1.46 [1.42-1.51]). Medication adherence rates were higher in those with resistant hypertension (93% vs 89.8%; P<.001). Chronic kidney disease (OR, 1.84; 95% CI, 1.78-1.90), diabetes mellitus (OR, 1.58; 95% CI, 1.53-1.63), and cardiovascular disease (OR, 1.34; 95% CI, 1.30-1.39) were also associated with higher risk of resistant hypertension.
CONCLUSION: In a more standardized hypertension treatment environment, we observed a rate of resistant hypertension comparable with that of previous studies using more fragmented data sources. Past observations have been limited due to nonrepresentative populations, reliability of the data, heterogeneity of the treatment environments, and less than ideal control rates. This cohort, which was established using an electronic medical record-based approach, has the potential to provide a better understanding of resistant hypertension and outcomes.
Copyright © 2013 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BP; CKD; ICD-9; International Classification of Diseases, Ninth Revision; KPSC; Kaiser Permanente Southern California; NHANES; National Health and Nutrition Examination Survey; OR; blood pressure; chronic kidney disease; odds ratio

Mesh:

Substances:

Year:  2013        PMID: 24079679      PMCID: PMC3909733          DOI: 10.1016/j.mayocp.2013.06.017

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  36 in total

Review 1.  Clinical practice. Resistant or difficult-to-control hypertension.

Authors:  Marvin Moser; John F Setaro
Journal:  N Engl J Med       Date:  2006-07-27       Impact factor: 91.245

2.  Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals.

Authors:  Eni C Okonofua; Kit N Simpson; Ammar Jesri; Shakaib U Rehman; Valerie L Durkalski; Brent M Egan
Journal:  Hypertension       Date:  2006-01-23       Impact factor: 10.190

3.  An increased visceral-subcutaneous adipose tissue ratio is associated with difficult-to-treat hypertension in men.

Authors:  Joji Ishikawa; Hajime Haimoto; Satoshi Hoshide; Kazuo Eguchi; Kazuyuki Shimada; Kazuomi Kario
Journal:  J Hypertens       Date:  2010-06       Impact factor: 4.844

4.  An empirical basis for standardizing adherence measures derived from administrative claims data among diabetic patients.

Authors:  Sudeep Karve; Mario A Cleves; Mark Helm; Teresa J Hudson; Donna S West; Bradley C Martin
Journal:  Med Care       Date:  2008-11       Impact factor: 2.983

5.  Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.

Authors:  Kenneth Jamerson; Michael A Weber; George L Bakris; Björn Dahlöf; Bertram Pitt; Victor Shi; Allen Hester; Jitendra Gupte; Marjorie Gatlin; Eric J Velazquez
Journal:  N Engl J Med       Date:  2008-12-04       Impact factor: 91.245

6.  Results of a retrospective, observational pilot study using electronic medical records to assess the prevalence and characteristics of patients with resistant hypertension in an ambulatory care setting.

Authors:  Carrie McAdam-Marx; Xiangyang Ye; Jennifer C Sung; Diana I Brixner; Kristijan H Kahler
Journal:  Clin Ther       Date:  2009-05       Impact factor: 3.393

7.  Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.

Authors:  David A Calhoun; Daniel Jones; Stephen Textor; David C Goff; Timothy P Murphy; Robert D Toto; Anthony White; William C Cushman; William White; Domenic Sica; Keith Ferdinand; Thomas D Giles; Bonita Falkner; Robert M Carey
Journal:  Circulation       Date:  2008-06-24       Impact factor: 29.690

8.  Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease.

Authors:  P Michael Ho; David J Magid; Susan M Shetterly; Kari L Olson; Thomas M Maddox; Pamela N Peterson; Frederick A Masoudi; John S Rumsfeld
Journal:  Am Heart J       Date:  2008-04       Impact factor: 4.749

9.  Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients.

Authors:  Giampiero Mazzaglia; Ettore Ambrosioni; Marianna Alacqua; Alessandro Filippi; Emiliano Sessa; Vincenzo Immordino; Claudio Borghi; Ovidio Brignoli; Achille P Caputi; Claudio Cricelli; Lorenzo G Mantovani
Journal:  Circulation       Date:  2009-10-05       Impact factor: 29.690

10.  A new equation to estimate glomerular filtration rate.

Authors:  Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh
Journal:  Ann Intern Med       Date:  2009-05-05       Impact factor: 25.391

View more
  72 in total

1.  A Health Profile of Arab Americans in Michigan: A Novel Approach to Using a Hospital Administrative Database.

Authors:  Florence J Dallo; Julie J Ruterbusch; Joseph David Kirma; Kendra Schwartz; Monty Fakhouri
Journal:  J Immigr Minor Health       Date:  2016-12

Review 2.  Ambulatory Blood Pressure Monitoring in the Diagnosis, Prognosis, and Management of Resistant Hypertension: Still a Matter of our Resistance?

Authors:  Antonios A Lazaridis; Pantelis A Sarafidis; Luis M Ruilope
Journal:  Curr Hypertens Rep       Date:  2015-10       Impact factor: 5.369

Review 3.  Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association.

Authors:  Emelia J Benjamin; Michael J Blaha; Stephanie E Chiuve; Mary Cushman; Sandeep R Das; Rajat Deo; Sarah D de Ferranti; James Floyd; Myriam Fornage; Cathleen Gillespie; Carmen R Isasi; Monik C Jiménez; Lori Chaffin Jordan; Suzanne E Judd; Daniel Lackland; Judith H Lichtman; Lynda Lisabeth; Simin Liu; Chris T Longenecker; Rachel H Mackey; Kunihiro Matsushita; Dariush Mozaffarian; Michael E Mussolino; Khurram Nasir; Robert W Neumar; Latha Palaniappan; Dilip K Pandey; Ravi R Thiagarajan; Mathew J Reeves; Matthew Ritchey; Carlos J Rodriguez; Gregory A Roth; Wayne D Rosamond; Comilla Sasson; Amytis Towfighi; Connie W Tsao; Melanie B Turner; Salim S Virani; Jenifer H Voeks; Joshua Z Willey; John T Wilkins; Jason Hy Wu; Heather M Alger; Sally S Wong; Paul Muntner
Journal:  Circulation       Date:  2017-01-25       Impact factor: 29.690

Review 4.  Resistant Hypertension: An Update of Experimental and Clinical Findings.

Authors:  Anping Cai; David A Calhoun
Journal:  Hypertension       Date:  2017-05-15       Impact factor: 10.190

5.  Resistant and Refractory Hypertension: Antihypertensive Treatment Resistance vs Treatment Failure.

Authors:  Mohammed Siddiqui; Tanja Dudenbostel; David A Calhoun
Journal:  Can J Cardiol       Date:  2015-07-08       Impact factor: 5.223

Review 6.  Apparent and true resistant hypertension: definition, prevalence and outcomes.

Authors:  E Judd; D A Calhoun
Journal:  J Hum Hypertens       Date:  2014-01-16       Impact factor: 3.012

7.  Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association.

Authors:  Robert M Carey; David A Calhoun; George L Bakris; Robert D Brook; Stacie L Daugherty; Cheryl R Dennison-Himmelfarb; Brent M Egan; John M Flack; Samuel S Gidding; Eric Judd; Daniel T Lackland; Cheryl L Laffer; Christopher Newton-Cheh; Steven M Smith; Sandra J Taler; Stephen C Textor; Tanya N Turan; William B White
Journal:  Hypertension       Date:  2018-11       Impact factor: 10.190

8.  Management of Resistant Hypertension: Do Not Give Up on Medication.

Authors:  Eric Judd; David A Calhoun
Journal:  Nephrol Self Assess Program       Date:  2014-03

9.  Hypertension in 2015: Resistant hypertension: impact and evolving treatment options.

Authors:  Lilach O Lerman; Stephen C Textor
Journal:  Nat Rev Nephrol       Date:  2015-12-14       Impact factor: 28.314

Review 10.  Resistant hypertension in diabetes mellitus.

Authors:  George Bayliss; Larry A Weinrauch; John A D'Elia
Journal:  Curr Diab Rep       Date:  2014-08       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.